165 related articles for article (PubMed ID: 18362270)
1. Is natalizumab overshooting its rebound?
Fox RJ; Kappos L
Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
[No Abstract] [Full Text] [Related]
2. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Vellinga MM; Castelijns JA; Barkhof F; Uitdehaag BM; Polman CH
Neurology; 2008 Mar; 70(13 Pt 2):1150-1. PubMed ID: 17872364
[No Abstract] [Full Text] [Related]
3. Natalizumab: bound to rebound?
Schiess N; Calabresi PA
Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
[No Abstract] [Full Text] [Related]
4. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
5. Human immune studies in multiple sclerosis.
Bar-Or A
Adv Neurol; 2006; 98():91-109. PubMed ID: 16400829
[No Abstract] [Full Text] [Related]
6. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
7. Blockade of chemokine signaling in patients with multiple sclerosis.
Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy].
Gold R; Hartung HP; Hohlfeld R
Dtsch Med Wochenschr; 2006 Jan; 131(1-2):31-4. PubMed ID: 16374741
[No Abstract] [Full Text] [Related]
9. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
10. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
Rice GP; Hartung HP; Calabresi PA
Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
[TBL] [Abstract][Full Text] [Related]
12. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Stüve O
J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab for multiple sclerosis.
Ransohoff RM
N Engl J Med; 2007 Jun; 356(25):2622-9. PubMed ID: 17582072
[No Abstract] [Full Text] [Related]
14. Drug Insight: using statins to treat neuroinflammatory disease.
Weber MS; Prod'homme T; Steinman L; Zamvil SS
Nat Clin Pract Neurol; 2005 Dec; 1(2):106-12. PubMed ID: 16932506
[TBL] [Abstract][Full Text] [Related]
15. Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
Hellwig K; Schimrigk S; Fischer M; Haghikia A; Müller T; Chan A; Gold R
Arch Neurol; 2008 May; 65(5):656-8. PubMed ID: 18474743
[TBL] [Abstract][Full Text] [Related]
16. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Stüve O; Cravens PD; Frohman EM; Phillips JT; Remington GM; von Geldern G; Cepok S; Singh MP; Tervaert JW; De Baets M; MacManus D; Miller DH; Radü EW; Cameron EM; Monson NL; Zhang S; Kim R; Hemmer B; Racke MK
Neurology; 2009 Feb; 72(5):396-401. PubMed ID: 18987352
[TBL] [Abstract][Full Text] [Related]
17. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
18. Campath-1H treatment of multiple sclerosis.
Jones JL; Coles AJ
Neurodegener Dis; 2008; 5(1):27-31. PubMed ID: 18075272
[TBL] [Abstract][Full Text] [Related]
19. Translating new insights into treatment optimisation in multiple sclerosis.
Fazekas F; Kieseier BC
J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
[No Abstract] [Full Text] [Related]
20. Getting specific: monoclonal antibodies in multiple sclerosis.
Lutterotti A; Martin R
Lancet Neurol; 2008 Jun; 7(6):538-47. PubMed ID: 18485317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
